The influence of treatment in specialized centers on survival of patients with thalassemia major

American Journal of Hematology

Volumn 84, Issue 5, 2009, Pages 317-318

  Forni, Gian Luca ^a   Puntoni, Matteo ^a   Boeri, Elio ^b   Terenzani, Laura ^a   Balocco, Manuela ^a  

^a GALLIERA HOSPITAL   (Italy)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; HEMOGLOBIN;

BLOOD TRANSFUSION; CHELATION; CLINICAL EVALUATION; CONGESTIVE HEART FAILURE; DISEASE REGISTRY; ELECTRONIC MEDICAL RECORD; HAZARD RATIO; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; INFECTION; ITALY; LETTER; MORTALITY; PATIENT COMPLIANCE; PATIENT REFERRAL; PEDIATRIC HOSPITAL; PHYSICIAN; PRIORITY JOURNAL; PROGNOSIS; SEX RATIO; SURVIVAL RATE; THALASSEMIA MAJOR; TREATMENT INDICATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; BETA-THALASSEMIA; CHILD; CHILD, PRESCHOOL; FEMALE; HOSPITALS, SPECIAL; HUMANS; INFANT; INFANT, NEWBORN; ITALY; KAPLAN-MEIERS ESTIMATE; MALE; REGISTRIES; YOUNG ADULT;

EID: 65649119698     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21398     Document Type: Letter

References (14)

1. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Survival and complications in thalassemia. Ann NY Acad Sci 2005;1054:40-47.
2. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: Data from the UK Thalassaemia Register. Lancet 2000;355:2051-2052.
3. Telfer P, Coen PG, Christou S, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica 2006;91:1187-1192.
4. Fung EB, Harmatz P, Milet M, et al. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload. Am J Hematol 2007;82:255-265.
5. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996;95:26-36. (Pubitemid 26071428)
6. Origa R, Bina P, Agus A, et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica 2005;90:1309-1314.
7. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006;91:873-880. (Pubitemid 44023139)
8. Modell B, Khan M, Darlison M, et al. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2008;10:42.
9. Borgna-Pignatti C, Zurlo MG, De Stefano P, et al. Survival in thalassemia with conventional treatment. Prog Clin Biol Res 1989;309:27-33.
10. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 1989;2:27-30.
11. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann NY Acad Sci 1998;850:227-231.
12. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-1193.
13. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006;107:3733-3737.
14. Delea TE, Hagiwara M, Thomas SK, et al. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. Am J Hematol 2008;83:263-270.